# OnCo record tnbc-basal-like-2 (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/tnbc-basal-like-2/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "tnbc-basal-like-2" ;
  schema:name "Basal-like 2 triple-negative breast cancer (BL2)"@en ;
  schema:alternateName "BL2 subtype"@en, "Basal-like 2 TNBC"@en, "Growth-factor signalling subtype of TNBC"@en ;
  schema:description "Basal-like 2 is a subtype of triple-negative breast cancer that shares the basal identity of basal-like 1 but is driven more by growth-factor signalling than by DNA damage, and it responded worst to standard chemotherapy before surgery in the studies that defined it, with pathological complete response in about one in five patients or fewer."@en ;
  schema:url <https://onco.cc/cancers/tnbc-basal-like-2/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Triple-negative_breast_cancer> ;
  schema:citation <https://doi.org/10.1172/jci45014>, <https://doi.org/10.1371/journal.pone.0157368>, <https://doi.org/10.1158/1078-0432.ccr-13-0799> ;
  onco:tag "breast", "tnbc", "subtype-page" ;
  onco:related <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-basal-like-1/>, <https://onco.cc/cancers/tnbc-mesenchymal/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/basal-like/>, <https://onco.cc/terms/pcr/> ;
  onco:standardOfCare <https://onco.cc/trials/keynote-522/>, <https://onco.cc/drugs/pembrolizumab/> .